Clinical Trial Update: Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating long-term antibody persistence of GlaxoSmithKline's HPV-16/18 L1 VLP AS04 vaccine (GSK-580299) in healthy adults and adolescents has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Human Papillomavirus Infection

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 3 | Status: WITHDRAWN